Formulation and Evaluation of Galantamine Hydrobromide Proniosome Gel for Alzheimer’s disease
Galantamine hydrobromide is formulated in tablets and capsules prescribed through oral delivery for the treatment of Alzheimer’s disease. However, oral delivery of drugs can cause severe side effects such as nausea, vomiting, and gastrointestinal disturbance. In the present research work, Galantamine hydrobromide is formulated as proniosome gel by Coacervation phase separation method using different surfactants such as Tweens and Spans. Overall eight formulations were developed and evaluated for various parameters. The prepared gels were viewed by naked eye to observe the colour of gel. Microscopical observations of the gels showed vesicles of optimum size from 3.030 mm (P2) - 3.735 mm (P5). The gel also showed optimum rate of spontaneity in the range 9.60 mm3x1000 (P7) to 11.80 mm3x1000 (P4) and entrapment efficiency of vesicles in the range 66.15% (P5) to 86.92% (P3). The gels had pH in suitable range of skin (5.92-6.9). The in vitro drug diffusion studies revealed that the drug diffusion was affected by the various surfactants used. The rank order of surfactant effect on in-vitro drug diffusion was Tween 80 > Tween 60 > Tween 40 >Tween 20 > Span 80 > Span 60 > Span 40 > Span 20. The proniosomal gel containing Tween 80 showed maximum drug diffusion (99.24%) and the gel containing Span 20 showed minimum drug diffusion (71.74%). FT-IR studies of optimized proniosome gel P8 revealed the absence of any chemical interactions between drug and carriers used.
Keywords: Galantamine hydrobromide, Proniosome gel, Coacervation phase separation method, Surfactants, in vitro drug diffusion studies.
2. Alzheimers association. Available at: https://www.alz.org/in/dementia-alzheimers-en.asp.
3. Mukherjee PK, Kumar V, Mal M, Houghton PJ, “Acetylcholinesterase inhibitors from plants” Phytomedicine, 2007; 14(4): 289-300.
4. Astha M, Anupriya K, Shilpi B, “Proniosomal gel as a carrier for transdermal drug delivery of clotrimazole” Int. J. Pharm. Pharm. Sci, 2012; 4(4): 610-614.
5. Arunothayanun P, Bernard MS, Craig DQ, Uchegbu IF, Florence AT, “The effect of processing variables on the physical characteristics of non-ionic surfactant vesicles (niosomes) formed from a hexadecyl diglycerol ether” Int. J. Pharm, 2000; 201(1):7–14.
6. Patel HN, Patel A, Patel VJ, Dave JB, Patel CN, “UV-spectrophotometric method development and validation for estimation of Galantamine Hydrobromide in tablet dosage form” J. Chem. Pharm. Res, 2010; 2(2): 44-49.
7. Smith RV, Stewart JT. Procurement and characterization of standard reference materials. 4th ed. Philadelphia: 1981.
8. Fang JY, Wamg RJ, Wu PC, Jsai YH, “Passive and iontophoretic delivery of three diclofenac salts across various skin types” Bio. Pharm. Bul, 2000; 23(11): 1357-1362.
9. Priyanka A, Biswajit M, “Design, development, physicochemical and invitro, invivo evaluation of transdermal patches containing diclofenac diethylammonium salt” J. Pharma. Sci, 2002; 91(9): 2078-88.
10. Martin A, Swarbrick J, Cammarata A. Polymer Science. 3rd ed. Bombay: K. M. Varghese Company; 1991.
11. Potts RO, Guy RH, “Predicting Skin Permeability” Pharm. Res, 1992; 9: 663-669.
12. Sankar V, Rukamani K, Durga S, Jailani S, “Proniosome as drug carrier” Pak. J. Pharm. Sci, 2010; 23(1):103-107.
13. Singh M, Gupta A, Prajapati SK, Balamurugan M, Bhatia D, “Design and Development of a Proniosomal Transdermal Drug Delivery System for Captopril” Trop. J. Pharm. Res, 2007; 6(2):687-693.
14. Mohammed Abu El-Enin AS, Khalifa M, Khalifa A, Dawaba AM, Dawaba HM, “Proniosomal gel-mediated topical delivery of fluconazole: Development, in vitro characterization, and microbiological evaluation” J. Adv. Pharm. Technol. Res, 2019; 10(1):20-26.
15. Mahmoud M, Omaima AS, Mohammed AH, Nagia AM, “Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes” Int. J. Pharm, 2008; 361:104-111.
16. Ren C, Fang L, Ling L, Wang Q, Liu S, Zhao L, He Z, “Design and in vivo evaluation of an indapamide transdermal patch” Int. J. Pharm, 2009; 370(1-2): 129-135.
17. Saroha K, Nanda S, Yadav N, “Proniosome Gel: potential carrier system in topical/transdermal delivery for drugs and cosmetics/cosmeceuticals - a review” (www.pharmainfo.net ).
18. Barry BW, “Is transdermal drug delivery research still important today” Drug Discov. Today, 2001; 6(19):967-971.
19. Runeman B, Faergemann J, Larko O, “Experimental candida albicans lesions in healthy humans: Dependence on skin pH” Acta. Derm. Venereol, 2000; 80: 421 – 424.
20. Abdul Rasool AA, Abbas HK, “Preparation and evaluation a proniosome gel for terbutaline sulphate as transdermal drug delivery system” Kufa J. Vet. Sci. 2010; 1(1): 78 – 93.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).